EP117: European Society of Cardiology Meeting Paris

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop is a practicing cardiologist and author dedicated to improving patient care through heart health education. In this episode, he discusses several groundbreaking trials and findings presented at the recent European Society of Cardiology meeting in Paris, including major advances in heart failure treatment and coronary artery disease management. Key Takeaways: The DAPA-HF trial demonstrated that dapagliflozin (a sodium-glucose transport inhibitor) reduces cardiovascular death and heart failure events by over 25%, with equal benefits in both diabetic and non-diabetic patients, marking a paradigm shift in heart failure management. SGLT2 inhibitors, originally developed for diabetes control, show significant cardiac benefits through mechanisms beyond glucose management, likely involving fluid balance and chemical messengers in the body. The Paragon HF trial showed that combination therapy with Entresto did not produce clinically significant improvements for patients with preserved ejection fraction heart failure, leaving this patient population without new treatment options. The COMPLETE trial revealed that addressing non-culprit coronary lesions (moderate to severe narrowings) at the time of acute coronary syndrome treatment reduces death and revascularization events by 25-50%. High sensitivity troponin testing safely identifies low-risk patients who can be discharged from emergency departments without heart damage, based on a study of approximately 20,000 patients. The THEMIS trial confirmed that dual antiplatelet therapy reduces recurrent cardiac events but increases bleeding risk, requiring careful patient-by-patient risk-benefit analysis for continuation beyond standard duration. New European lipid guidelines recommend lowering LDL cholesterol targets to 1.4 millimoles per liter (55 mg/dL) for very high-risk patients, and to 1.0 millimole per liter (40 mg/dL) for those who fail standard therapy, achievable primarily through PCSK9 inhibitors. Supplemental oxygen provides no benefit for acute coronary syndrome patients with adequate oxygen saturation, though it remains necessary for those with low oxygen levels.